Yes, it is technically possible to get polio after being vaccinated, but the risk is extraordinarily small. Three doses of the inactivated polio vaccine (IPV), the type used in the United States and most high-income countries, provide at least 99% protection against paralytic polio. That means the vaccine works in nearly every person who completes the full series, and protection likely lasts a lifetime.
Still, “nearly every person” is not “every person.” Understanding the rare scenarios where vaccination falls short can help put the real risk in perspective.
How Well the Vaccine Protects
Protection builds with each dose. Two doses of IPV provide at least 90% protection against paralytic polio, and a third dose pushes that above 99%. The standard childhood schedule in the U.S. includes four doses total, given at 2 months, 4 months, 6 to 18 months, and 4 to 6 years. Each dose strengthens and extends immunity.
Antibody levels can dip below detectable levels over the decades following vaccination. That sounds alarming, but it does not appear to mean you’ve lost protection. The immune system retains memory of the virus, and there is no evidence that waning antibody levels after a completed primary series leads to vulnerability. The World Health Organization’s position is that protection against paralytic disease lasts for decades and may well be lifelong.
The Gap Between Preventing Disease and Preventing Infection
This is a nuance most people don’t know about. The injectable vaccine used in the U.S. is excellent at preventing paralysis, but it does not create strong immunity in the lining of your gut. Poliovirus enters the body through the mouth and multiplies in the intestines. The older oral vaccine (OPV), which uses a weakened live virus, triggers a robust immune response right there in the gut, blocking the virus at its point of entry.
IPV, by contrast, trains your bloodstream’s immune defenses. If poliovirus got into your intestines, IPV would prevent it from reaching your nervous system and causing paralysis. But the virus could still briefly replicate in your gut and pass through your stool. In practical terms, a fully vaccinated person exposed to poliovirus could, in rare circumstances, carry and shed the virus without ever getting sick. This matters more for public health strategy than for individual risk, but it explains why oral vaccine campaigns remain essential in countries where polio still circulates.
Who Faces Higher Risk Despite Vaccination
The small number of people for whom the vaccine may not provide full protection overwhelmingly fall into one category: those with certain immune system disorders that impair the body’s ability to produce antibodies. Antibodies are the main weapon the immune system uses to neutralize poliovirus. When the machinery that produces them is broken or absent, the virus can persist in the body far longer than it should.
The conditions most strongly linked to this problem are primary immunodeficiencies affecting B cells, the white blood cells responsible for making antibodies. These include X-linked agammaglobulinemia (roughly 1 in 700,000 people), common variable immunodeficiency (about 1 in 50,000), and severe combined immunodeficiency. In a WHO registry tracking these cases, about a third of affected patients had severe combined immunodeficiency, while another third had agammaglobulinemia or common variable immunodeficiency. Paralysis rates among these patients were high, with 96% of those with agammaglobulinemia developing paralysis.
Notably, HIV infection does not appear to carry the same elevated risk. Only two cases of vaccine-related paralytic polio have ever been reported in people with HIV, both linked to the oral vaccine.
For people with healthy immune systems who completed the vaccine series, the risk of paralytic polio is vanishingly close to zero.
Vaccine-Derived Polio: A Separate Issue
There is another way polio cases occur in vaccinated populations, and it involves the oral vaccine itself. OPV contains weakened live poliovirus. In extremely rare cases, this weakened virus mutates as it passes through undervaccinated communities and regains the ability to cause paralysis. These are called circulating vaccine-derived polioviruses.
The global risk of vaccine-associated paralytic polio from OPV is estimated at roughly 4.7 cases per million births. That translates to an estimated 400 to 500 cases worldwide per year. The risk varies enormously by country and vaccination coverage. Brazil recorded among the lowest rates at about 1 case per 10.7 million OPV doses, while Romania historically reported the highest at 1 case per 35,000 doses.
This is largely irrelevant if you live in the U.S. or another country that uses only IPV. The injectable vaccine contains killed virus that cannot replicate or mutate, so it carries zero risk of vaccine-derived polio. The U.S. switched exclusively to IPV in 2000 for exactly this reason. In 2024, 11 cases of circulating vaccine-derived poliovirus were reported globally, nearly all in the Democratic Republic of the Congo.
What Breakthrough Cases Look Like
In the rare documented cases where a vaccinated person develops polio, the hallmark symptom is the same as in unvaccinated patients: acute flaccid paralysis, a sudden onset of weakness or loss of movement in one or more limbs. In one published case of a child with an undiagnosed immune deficiency, the first signs were a regression in motor skills, difficulty standing with support, and trouble using the arms. Fever and asymmetric leg weakness followed.
Most poliovirus infections, even in unvaccinated people, never progress to paralysis. About 72% of infections cause no symptoms at all, and most of the rest cause mild flu-like illness. Vaccination shifts the odds even further toward a mild or invisible course. If a vaccinated person with a healthy immune system were somehow exposed to poliovirus, the most likely outcome by far is that their immune system would neutralize the virus before it caused any noticeable illness.
Practical Takeaways for Vaccinated Adults
If you completed the standard childhood polio series, you are protected. Adults in the U.S. with no particular risk factors do not need a booster dose. The one exception is travel: if you’re heading to a country where polio still circulates, a single lifetime booster of IPV is recommended if you completed your primary series as a child.
For parents, the key is simply making sure your child receives all four scheduled doses. Partial vaccination leaves a real gap. Two doses bring protection to about 90%, which sounds high until you compare it to the 99%-plus protection offered by the full series. That last stretch of coverage matters, especially in a world where poliovirus, though nearly eradicated, has not disappeared entirely.